HER2-Low, HER2-Positive, and HER2-Mutated: Similar Words, Different Treatment Questions

Four labels, one protein, different questions

Cancer coverage now uses HER2-positive, HER2-low, HER2-ultralow, and HER2-mutated, often in the same week. The words look like variations on a theme. They are not. Some describe how much of a protein a tumor makes. One describes a change in a gene.

Mixing them up leads people to expect a treatment they may not be eligible for, or to dismiss one they are.

This page explains public sources. It is not medical advice and does not suggest a test or treatment.

What HER2 is

NCI defines HER2 as a protein involved in normal cell growth. Some cancer cells make it in larger than normal amounts, which can make them grow and spread more quickly.

NCI lists breast, ovarian, bladder, pancreatic, stomach, and esophageal cancers among those where this can happen. It also notes that measuring HER2 on some cancer cells can help plan treatment. The same protein appears in older writing as HER2/neu, c-erbB-2, or human epidermal growth factor receptor 2.

The categories come from a scoring system

The protein categories are not descriptive adjectives. They are defined test results, and drug labels tie eligibility to them precisely.

The prescribing information for fam-trastuzumab deruxtecan-nxki spells this out. Its HER2-positive breast cancer indication is written for IHC 3+ or ISH-positive disease. Its HER2-low indication covers IHC 1+ or IHC 2+ with negative ISH. Its HER2-ultralow indication covers IHC 0 with membrane staining, in hormone-receptor-positive disease that has progressed on endocrine therapy.

IHC means immunohistochemistry, a stain that estimates how much protein is present. ISH looks for extra copies of the gene. A pathologist reads and scores the slide. That scoring step is where the category is decided.

FDA approved the HER2-low and HER2-ultralow breast cancer use, and the label requires an FDA-approved test to determine the result. Our guide to biomarker testing and precision medicine explains how these tests fit into treatment planning.

A mutation is a different finding

A HER2 mutation is a change in the DNA sequence of the gene. It is found by sequencing, not by staining. A tumor can carry a HER2 mutation without making unusual amounts of HER2 protein.

The same drug's label carries a separate indication for HER2-mutant non-small cell lung cancer. It sits apart from the breast cancer indications for a reason. Different test, different disease, different evidence.

So "HER2-mutated" in a lung cancer story and "HER2-low" in a breast cancer story are not two versions of the same news.

Cancer type still matters

FDA has granted an accelerated approval for HER2-positive solid tumors at IHC 3+, across several cancer types. That is genuinely broad, and it is also narrow in its own way. It applies to a specific score, after prior systemic treatment, and under accelerated approval rather than traditional approval.

An approval in breast cancer does not automatically extend to lung, gastric, or colorectal cancer. Each indication was built on its own trials. Our overview of breast cancer and our page on HER2-positive and HER2-low breast cancer cover how these results are used in practice.

What to check in a HER2 headline

• Which cancer type is being discussed?
• Was HER2 measured by protein staining, gene copy number, or sequencing?
• What score or cutoff defines the group?
• Is the disease early-stage or metastatic, and what treatment came before?
• Was the category defined before the trial or after the results were seen?

A category invented after the data are in hand needs confirmation in a separate study before it can support broad conclusions.

Four confusions worth avoiding

• HER2-low is not a mild form of HER2-positive. It is a different category with different evidence.
• A HER2 mutation is not the same as HER2 protein overexpression.
• An approval in one cancer does not carry over to another.
• A borderline or uncertain score may warrant review or retesting, which is a conversation for the care team.

Questions to ask about a pathology report

• What was tested, by which method, and what was the result?
• Does that result match an approved option, a trial, or neither?
• Should the sample be retested or reviewed by another pathologist?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.